* See Item 5 of this Schedule 13D.

* See Item 5 of this Schedule 13D.

* See Item 5 of this Schedule 13D.

* See Item 5 of this Schedule 13D.

* See Item 5 of this Schedule 13D.

The following constitutes the Schedule 13D filed by the undersigned (the “Schedule 13D”).

This statement relates to the Class A Common Stock, par value $0.0001 per share (the “Shares”), of Real Goods Solar, Inc., a Colorado corporation (the “Issuer”). The address of the principal executive offices of the Issuer is 110 16 ^th Street, Suite 300, Denver, Colorado 80202.

This statement is filed by:

Each of the foregoing is referred to as a “Reporting Person” and collectively as the “Reporting Persons.” Each of the Reporting Persons is party to that certain Joint Filing Agreement, as further described in Item 6. Accordingly, the Reporting Persons are hereby filing a joint Schedule 13D.

(b)       The address of the principal office of each of the Reporting Persons is 205 East 42nd Street, 20th Floor, New York, New York 10017. The officers and directors of Iroquois Master Fund and their principal occupations and business addresses are set forth on Schedule A to the Schedule 13D and are incorporated by reference in this Item 2.

(c)       The principal business of Iroquois Master Fund is serving as a private investment fund. The principal business of Iroquois Capital is serving as an investment adviser that provides investment advisory services to Iroquois Master Fund. The principal business of ICIG is serving as a private investment fund. The principal occupation of Mr. Abbe is serving as the President of Iroquois Capital and managing member of ICIG. The principal occupation of Ms. Page is serving as Chief Operating Officer, Compliance Officer of Iroquois Capital.

(d)       No Reporting Person, nor any person listed on Schedule A to the Schedule 13D, has, during the last five years, been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).

(e)       No Reporting Person, nor any person listed on Schedule A to the Schedule 13D, has, during the last five years, been party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

(f)       Mr. Abbe and Ms. Page are citizens of the United States of America. The citizenship of the persons listed on Schedule A to the Schedule 13D is set forth therein.

The Shares purchased by Iroquois Master Fund were purchased with working capital (which may, at any given time, include margin loans made by brokerage firms in the ordinary course of business) in open market purchases. The aggregate purchase price of the 5,000 Shares purchased by Iroquois Master Fund is approximately $8,572, including brokerage commissions.

Pursuant to a Cooperation Agreement with the Issuer dated January 2, 2018 (as defined in Item 4 below), Iroquois Master Fund was issued 456,000 unregistered and restricted Shares and ICIG was issued 144,000 unregistered and restricted Shares.

Series K Warrants

On February 6, 2017, Iroquois Master Fund and ICIG each acquired warrants to purchase 419,355 and 255,806 Shares, respectively (collectively, the “Series K Warrants”). The Series K Warrants entitle the holders to purchase Shares at an exercise price of $3.10 per share for a period of five years of the date of issuance. The Series K Warrants may be exercised for cash or on a cashless basis. The Series K Warrants are subject to a beneficial ownership limitation such that the holder may not acquire Shares upon the exercise thereof if the holder would beneficially own (as defined in the Series K Warrants) in excess of 4.99% of the number of Shares outstanding immediately after such exercise, or the holder, with its affiliates, would beneficially own in excess of 9.99% of the number of Shares outstanding immediately after such exercise; provided, that such limitation may be increased or decreased at any time by the holder upon not less than 61 days’ prior written notice to the Issuer.

The foregoing is only a brief description of the material terms of the Series K Warrants. The foregoing descriptions are qualified in their entirety by reference to the full text of the form of the Series K Warrants, which were filed by the Issuer as Exhibit 4.1 to a Current Report on Form 8-K filed by the Issuer with the SEC on February 2, 2017 and are incorporated by reference herein.

Series M Warrants

On February 10, 2017, Iroquois Master Fund and ICIG each acquired warrants to purchase 113,750 and 46,224 Shares, respectively (collectively, the “Series M Warrants”). The Series M Warrants entitle the holders to purchase Shares at an exercise price of $2.40 per share for a period of five years of the date of issuance. The Series M Warrants may be exercised for cash or on a cashless basis. The Series M Warrants are subject to a beneficial ownership limitation such that the holder may not acquire Shares upon the exercise thereof if the holder would beneficially own (as defined in the Series M Warrants) in excess of 4.99% of the number of Shares outstanding immediately after such exercise, or the holder, with its affiliates, would beneficially own in excess of 9.99% of the number of Shares outstanding immediately after such exercise; provided, that such limitation may be increased or decreased at any time by the holder upon not less than 61 days’ prior written notice to the Issuer.

The foregoing is only a brief description of the material terms of the Series M Warrants. The foregoing descriptions are qualified in their entirety by reference to the full text of the form of the Series M Warrants, which were filed by the Issuer as Exhibit 4.1 to a Current Report on Form 8-K filed by the Issuer with the SEC on February 8, 2017 and are incorporated by reference herein.

On January 2, 2018, each of the Reporting Persons (collectively, “Iroquois”) entered into a Cooperation Agreement (the “Agreement”) with the Issuer regarding Iroquois’ solicitation of proxies in opposition to the election of directors at the Issuer’s 2017 annual meeting of shareholders (the “Annual Meeting”). The following description of the Agreement is qualified in its entirety by reference to the Agreement, which is attached as Exhibit 99.2 hereto and is incorporated herein by reference. Terms that are not otherwise defined herein have the meanings ascribed to them in the Agreement.

Pursuant to the Agreement, Iroquois agreed to (i) withdraw and not resubmit its Definitive Proxy Statement filed with the Securities and Exchange Commission (the “SEC”) on July 24, 2017 and (ii) to appear at the Annual Meeting in person or by proxy and to vote all of its Shares in favor of (a) the election of the Issuer’s director nominees, (b) the approval of an amendment to the Issuer’s 2008 Long-Term Incentive Plan to increase the number of shares authorized for issuance and the number of shares that a participant may receive in a fiscal year, and (c) the ratification of the appointment of Moss Adams LLP to audit the Issuer’s consolidated financial statements for the 2017 fiscal year.

Under the terms of the Agreement, the Issuer agreed to issue and deliver to Iroquois Master Fund and ICIG 456,000 and 144,000 unregistered and restricted Shares, respectively, as reimbursement for expenses incurred in connection with the Annual Meeting and the negotiation, execution and effectuation of the Agreement. Further, the Issuer and Iroquois agreed to cooperate in good faith to enter into a registration rights agreement, with customary terms reasonably acceptable to the Issuer, granting Iroquois piggyback registration rights with respect to the Shares Iroquois received pursuant to the Agreement.

In addition, Iroquois agreed to certain customary standstill provisions and voting commitments until thirty (30) calendar days prior to the expiration of the advance notice period for the submission by shareholders of director nominations for consideration at the Issuer’s 2022 annual meeting of shareholders (the “Standstill Period”), as set forth in the advance notice provisions of the Issuer’s Bylaws. The Agreement also contains mutual releases and mutual non-disparagement obligations.

No Reporting Person has any present plan or proposal which would relate to or result in any of the matters set forth in subparagraphs (a) - (j) of Item 4 of Schedule 13D except as set forth herein or such as would occur upon or in connection with completion of, or following, any of the actions discussed herein. The Reporting Persons intend to review their investment in the Issuer on a continuing basis. Depending on various factors including, without limitation, the Issuer’s financial position and investment strategy, the price levels of the Shares, conditions in the securities markets and general economic and industry conditions, the Reporting Persons may in the future take such actions with respect to their investment in the Issuer as they deem appropriate including, without limitation, continuing to engaging in communications with management and the Board of the Issuer, engaging in discussions with stockholders of the Issuer and others about the Issuer and the Reporting Persons’ investment, making proposals to the Issuer concerning changes to the capitalization, ownership structure, board structure (including board composition) or operations of the Issuer, purchasing additional Shares, selling some or all of their Shares, engaging in short selling of or any hedging or similar transaction with respect to the Shares, or changing their intention with respect to any and all matters referred to in Item 4.

The Agreement was also included as Exhibit 10.1 to a Current Report on Form 8-K filed by the Issuer with the SEC on January 3, 2018.

The aggregate percentage of Shares reported owned by each person named herein is based upon 9,551,845 Shares, which represents (1) the 8,951,845 Shares outstanding, as of January 4, 2018, which is the total number of Shares outstanding as reported in the Issuer’s Current Report on Form 8-K, filed with the SEC on January 4, 2018, plus (2) the 600,000 unregistered and restricted Shares issued pursuant to the Cooperation Agreement, as further described in Item 4.

Excluded from the Reporting Persons’ beneficial ownership are 835,135 Shares issuable upon the exercise of certain warrants of the Issuer subject to a 4.99% blocker provision (the “Warrants”) owned by each of Iroquois Master Fund and ICIG, due to a conversion cap that precludes the holder thereof from converting such warrants to the extent that the holder would, after such exercise, beneficially own (as determined in accordance with Section 13(d) of the Securities Exchange Act of 1934, as amended) in excess of 4.99% of the Shares outstanding (the “Beneficial Ownership Limitation”).

Percentage: Approximately 4.8%

B.       Iroquois Capital

Percentage: Approximately 4.8%

Percentage: Approximately 1.5%

Percentage: Approximately 6.3%

Percentage: Approximately 4.8%

3. Sole power to dispose or direct the disposition: 0
4. Shared power to dispose or direct the disposition: 461,000

Each Reporting Person, as a member of a “group” with the other Reporting Persons for the purposes of Section 13(d)(3) of the Securities Exchange Act of 1934, as amended, may be deemed the beneficial owner of the Shares directly owned by the other Reporting Persons. Each Reporting Person disclaims beneficial ownership of such Shares except to the extent of his or its pecuniary interest therein.

On January 2, 2018, the Reporting Persons entered into a Cooperation Agreement, as described further in Item 4, with the Issuer. Pursuant to the Cooperation Agreement, the Reporting Persons were issued 600,000 unregistered and restricted Shares. A copy of the Cooperation Agreement was attached as Exhibit 10.1 to the Issuer’s Current Report on Form 8-K, filed with the SEC on January 3, 2018, and is incorporated herein by reference.

On January 16, 2018, the Reporting Persons entered into a Joint Filing Agreement in which the Reporting Persons agreed to the joint filing on behalf of each of them of statements on Schedule 13D with respect to the securities of the Issuer to the extent required by applicable law. The Joint Filing Agreement is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Other than as described herein, there are no contracts, arrangements, understandings or relationships among the Reporting Persons, or between the Reporting Persons and any other person, with respect to the securities of the Issuer.

SIGNATURES

After reasonable inquiry and to the best of his knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

Dated: January 16, 2018

SCHEDULE A

Directors of Iroquois Master Fund Ltd.